Kornimate/medical-research-clean huggingface dataset:
prevalence of sarcopenia and sarcopenic obesity in older adults

Conditions: Sarcopenia; Sarcopenic Obesity; Osteopenia, Osteoporosis

Summary: syndromes such as sarcopenia, sarcopenic obesity and osteosarcopenic obesity are commonly seen in older adults. they result from the impairment of muscle, bone and adipose tissue. thus, they lead to a decrease in quality of life and increase morbidity and mortality. the aim of this study is to report the prevalence of sarcopenia, sarcopenic obesity and osteosarcopenic obesity in community-dwelling outpatient older adults and to investigate the related factors.


Eligibility criteria:
inclusion criteria: * being at the age of 65 or older * being able to complete 4-m walk test exclusion criteria: * \<24 points on mini-mental state examination * 12 points or higher on geriatric depression scale

Keywords: older adults
low molecular weight heparin in pregnancies with unexplained stillbirths

Conditions: Unexplained Stillbirth

Summary: bemiparin for pregnant women with abnormal umbilical artery doppler ultrasound

152 women with history of unexplained stillbirths were identified , umbilical arty doppler ultrasound was conducted for them at 20-22 weeks gestation . they were divided into two group , group one are those with abnormal resistant index (= or more than 0.6) thy received bemiparin 2500 iu subcutaneously daily up to 24 hours before delivery . group 2 with normal umbilical artery resistant index received no any interventions just routine antenatal follow up .

Eligibility criteria:
inclusion criteria: * second pregnancy after previous unexplained fetal death * singleton pregnancy * no any medical disorders during pregnancy like diabetes or systemic lupus erythematosus * normally located placenta * no congenital fetal anomalies * patient accept to participate exclusion criteria: * confirmed thrombophilia * twin pregnancies * refused to participate

Keywords: unexplained stillbirth low molecular weight heparin umbilical artery doppler ultrasound antenatal care
assessment of neural inspiratory time through semg and emgdi

Conditions: Copd; Ventilation; Rehabilitation

Summary: the onset and offset of the neural inspiratory time are fundamentally important measurements in studies of patientventilator interaction, where the level of assistance delivered by the ventilator is controlled by the patient's demand. the onset of neural inspiratory time can be determined in esophageal pressure, transdiaphragmatic pressure, and emg signals. the investigator compare the onset measured by emg, esophageal and transdiaphragmatic pressure, and consider that the correlation between them is well in different conditions.

the onset and offset of the neural inspiratory time are fundamentally important measurements in studies of patien-tventilator interaction, where the level of assistance delivered by the ventilator is controlled by the patient's demand. patient-ventilator asynchrony evaluated using the time lag between onset of the neural inspiratory time and the onset of a mechanical ventilation signal. the onset of neural inspiratory time can be determined in esophageal pressure, transdiaphragmatic pressure, and emg signals. the investigator compare the onset measured by emg, esophageal and transdiaphragmatic pressure, and consider that the correlation between them is well in three different conditions.

Eligibility criteria:
inclusion criteria: * normal cardio-pulmonary function * without low inspiratory muscle strength * non-smoker * without history of the nervous system and respiratory system disease * sever to very severe stable stage exclusion criteria: * systemic application of corticosteroids nearly 4 weeks
influence of co-diagnosis of chronic fatigue syndrome in patients with fibromyalgia.

Conditions: Fibromyalgia; Chronic Fatigue Syndrome; Comorbidities and Coexisting Conditions

Summary: the purpose of this study is to evaluate differences in neuroimmunoendocrine response and quality of live in patients diagnosed with fibromyalgia, with or without a co-diagnosis of chronic fatigue syndrome.

the limited literature published in concordant relation affects the chronic fatigue syndrome comorbidity in the daily life of fibromyalgia patients leads us to design this study with the main objective of evaluating differences in the quality of life associated with pain and stress, mainly in relation to levels of physical activity, sedentary lifestyle and sleep in patients diagnosed with fibromyalgia, with or without a parallel co-diagnosis of chronic fatigue syndrome.

Eligibility criteria:
inclusion criteria: * fibromyalgia and/or chronic fatigue syndrome diagnosis by rheumatologists or internal medicine professionals. * age not less than 40 years old and not more than 65 years old. exclusion criteria: * suffering from diagnosed "major depression". * suffer diagnosed multiple chemical sensitivity. * corticosteroid treatment or anti-cytokine therapies. * periodically carry out programmed therapeutic physical activity in the two months prior to the accelerometry tests.
coaching performance driven practice change in the context of value based purchasing under new york medicaid

Conditions: Opioid-use Disorder; Substance Use Disorders

Summary: this project will develop and test quality measures for and a facilitation model to help addictions treatment clinics increase use of medicines for opioid use disorders, retain clients longer in care, and help more people move into successful recovery. at the end of the project, we will have developed specific training and coaching protocols as well as electronic clinical support tools to guide quality improvement that can be disseminated within new york and the rest of the country. the study will test a clinic-level intervention that uses external facilitators to provide guidance to addictions clinics and contain three key components: 1) training on data driven management; 2) training and guidance on patient-centered care and oud medication; and 3) electronic tools for shared decision making and patient progress monitoring.

there will be 4 sources of data examined in this study: 3 at the patient level and 1 at the staff level. the sources of patient data include: 1) state administrative data from all clients receiving treatment at the enrolled clinics (\~7,950); 2) a subsample (1,200) who will be recruited directly from the clinics to complete patient-reported outcome assessments, and 3) treatment progress data for clients will also be collected. for our administrative source of data, a final study population of approximately 7,950 individuals who are receiving treatment in the 30 enrolled outpatient treatment clinics for oud is anticipated. clinics will be located in the new york city metropolitan region (including nassau, westchester, and rockland counties) and the capital region (including albany, rensselaer, saratoga, montgomery, schenectady, and schoharie counties). staff at each enrolled clinic will also be interviewed and surveyed.

Eligibility criteria:
inclusion criteria: * substance use disorder clinics in the regions surrounding new york city and the new york capital region with annual census of 50 or greater. * all staff and patients from participating clinics will be eligible to participate in the study. * inclusion in the analyses using administrative data will be limited to those enrolled in medicaid and not co-insured with medicare (individuals ages greater than 64 and those with federally determined disability). exclusion criteria: * patients who are not working/being treated at substance use disorder clinics with less than 50 clients per year.
national longitudinal cohort of hematological diseases- autoimmune hemolytic anemia

Conditions: AIHA - Warm Autoimmune Hemolytic Anemia; AIHA - Cold Autoimmune Hemolytic Anemia; Autoimmune Hemolytic Anemia Mixed Type

Summary: hematological diseases are disorders of the blood and hematopoietic organs. the current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in china. there is a lack of comprehensive and large-scale prospective cohort studies in hematology. the objectives of this study are to investigate the incidence and risk factors of autoimmune hemolytic anemia (aiha) and to analyze the treatment effectiveness, patient prognosis and healthcare costs in china. 1. analyze the demographic and clinical characteristics of patients with aiha, including sex, age, disease severity, and other relevant factors. 2. examine disease features of aiha patients, such as biochemical and hematological indicators 3. assess treatment patterns and real-world effectiveness in aiha patients. 4. evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with aiha. * hemoglobin\<100g/l * subjects treated at the institute of hematology and blood diseases hospital from jan 1, 2001. exclusion criteria: * subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities). * subject with alcohol or drug dependence may reduce their compliance with the study. * subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.

Keywords: autoimmune hemolytic anemia treatment patterns hematologic response
adrenalectomy for solitary adrenal gland metastases

Conditions: Adrenal Gland Metastases; Adrenalectomy

Summary: the adrenal glands are one of the most common organs involved in metastatic disease. metastases are the second most common type of adrenal mass, second only to adenomas. it is a frequent finding during autopsy with a reported rate as high as 27% in patients with known primary malignancy. although several studies have found an increased survival in patients who undergo resection of solitary adrenal metastases the indications for adrenalectomy in cases of metastatic adrenal tumor remain controversial. collinson et al reported an increased survival in patients with melanoma. median survival was 16 months for patients who underwent adrenalectomy compared to 5 months for patients with documented adrenal metastases treated non surgically. the aim of this study is to compare retrospectively in case and control study, performing adrenalectomy, open or laparoscopic, versus supportive treatment for patients with solitary adrenal gland metastases. the investigators will review charts of patients between january 1994 and november 2009 who had adrenal gland metastases. the variables the inevstigators will compare are mortality, morbidity, primary tumour sites, histological cell type, age, tumour size, presence of synchronous metastases, mean time from diagnosis of primary tumor to treatment of adrenal metastases, indication for adrenalectomy, partial versus total adrenalectomy, suspected versus confirmed metastatic disease.


Eligibility criteria:
inclusion criteria: * metastatic disease to the adrenal gland exclusion criteria: * primary adrenal neoplasm

Keywords: adrenalectomy metastasis morbidity mortality survival
study of glutathione, vitamin c and cysteine in children with autism and severe behavior problems

Conditions: Autism; Severe Behavior Disorder

Summary: this is a double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of glutathione alone or glutathione, vitamin c and nac treatment in children with autism who also have severe behavior problems. the investigators hypothesis is that children with autism will show improvement in both learning capabilities and behavior with either glutathione, or glutathione, vitamin c and nac therapy.

this is a prospective, single center, double-blind, randomized pilot study in children and adolescents with autism and severe behavior disorders. all subjects will undergo initial screening procedures to determine eligibility. they will then be randomized to either 8 weeks of placebo or 8 weeks of glutathione or glutathione, vitamin c and n-acetylcysteine. they will receive intravenous treatment weekly and will have ongoing behavioral studies during this period. following 8 weeks of therapy, they will have a week without treatment then will cross-over to the alternate therapy for weekly intravenous infusions and behavioral testing. in addition to baseline hematology and chemistries, baseline oxidized and reduced glutathione will be measured. these parameters will be repeated at the end of each 8 week course of therapy.

Eligibility criteria:
inclusion criteria: * age 5 to 16 years, inclusive * diagnosed with autism using the adi-r (autism diagnostic interview-revised) * abc irritability/agitation subscale score (aberrant behavior checklist subscale) ≥ 18 * cgi-s score (clinical global impression-severity scale) ≥ 4 * must be drug naïve or on a stable dose of medication(s) and educational/behavioral interventions for one month prior to participation * parent/legal guardian must provide written consent and required research authorization (i.e. hipaa) prior to the performance of any study procedures. exclusion criteria: * presence of another disorder on the autism spectrum including pdd-nos (pervasive developmental disorder not otherwise specified), asperger's, and rett's syndrome * patient with a known cause of autism such as fragile x * evidence of significant renal dysfunction (e.g. gfr estimated by the schwartz formula \ 2.5 x upper limit of normal for age) * evidence of significant hepatic dysfunction (serum transaminases \> 2.5 x the upper limit of normal) * known hypersensitivity to glutathione, vitamin c or nac * pregnant or lactating female * inability of subject and parent to be able to comply with requirements for study visits and procedures * presence of major mental illness * history of antioxidant supplementation.

Keywords: autism severe behavior disorder glutathione antioxidants
changes in cardiovascular and sleep quality parameters under eurythmy therapy and tai chi in comparison to standard care - a substudy of the entaier trial

Conditions: Fall Patients; Elderly Patients; Chronic Disease; Sleep Quality; Cardiovascular System; Tai Chi; Eurythmy Therapy

Summary: entaier study is a multicentre randomized controlled trial to assess the efficacy and safety of eurythmy therapy and tai chi in comparison to standard care in chronically ill elderly patients with increased risk of falling. subjects will be randomized to eurythmy therapy or tai chi or standard care alone. to investigate the changes in cardiovascular and sleep quality parameters under eurythmy therapy and tai chi in comparison to standard care in this trial, a substudy will be conducted only at the arcim institute. the substudy will recruit enrolled participants from the entaier trial to record various cardiovascular and sleep quality parameters. the aim is to compare changes in cardiovascular and sleep quality parameters under eurythmy therapy, tai chi and standard care alone in chronically ill elderly patients with increased risk of falling.

this is an optional substudy of a multi-centre, parallel-group, three-arm randomized controlled trial - entaier trial - to compare the changes in cardiovascular and sleep quality parameters under eurythmy therapy and tai chi in comparison to standard care in chronically ill elderly patients with increased risk of falling (see drks-id: drks00016609). subjects who consent to enroll in entaier will be asked to participate in this substudy. the main focus of this substudy is on assessing the effects of tai chi and eurythmy on the vegetative nervous system by measuring various parameters of heart rate variability and pulse wave analysis. in addition, the effects on sleep quality will be assessed. participants of the substudy will undergo a measurement of heart rate variability with a long-term-ecg (bittium faros 360 tm), a pulse wave analysis, recorded with a vital function monitor (vitaguard® 3100 monitor, getemed, germany), and a blood pressure measurement and they fill in a sleep quality questionnaire (pittsburgh sleep quality index, psqi) at baseline and after 3, 6 and 12 months.

Eligibility criteria:
inclusion criteria: * to be eligible for this substudy, subjects must be enrolled in entaier main study and provide separate written informed consent for eyt_12 substudy. see drks-id: drks00016609 for inclusion criteria into entaier main study exclusion criteria for substudy: * cardiac pacemaker * atrial fibrillation (documented in medical reports) * to be eligible for this substudy, subjects must be enrolled in entaier main study and provide separate written informed consent for eyt_12 substudy. see drks-id: drks00016609 for exclusion criteria into entaier main study

Keywords: tai chi; eurythmy; hrv; pwa; sleep quality; fall prevention
allogene mscs transplantation in liver for patients with chronic liver diseases through portal vein by ultrasound guiding

Conditions: Allogene Transplantation; Chronic Liver Diseases Patients; Through Portal Vein by Ultrasound Guiding

Summary: allogene mscs transplantation will be performed in patients with chronic liver diseases through portal vein by ultrasound guiding and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.


Eligibility criteria:
inclusion criteria: 1. chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease. 2. age: 15-65 years old. exclusion criteria: 1. pregnant women and women in lactation. 2. other systems and organs disfunction 3. space-occupying lesion were found in liver. 4. concurrent infection with hiv and other immunodeficiency diseases. 5. dic and active bleeding were confirmed.

Keywords: allogene mscs transplantation chronic liver diseases portal vein
neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy

Conditions: Hypoxic-Ischemic Encephalopathy

Summary: the purpose of this study is to investigate the efficacy and safety of allogenic neural progenitor cell and paracrine factors of human mesenchymal stem cells for patients with moderate/severe hypoxic-ischemic encephalopathy

neonates diagnosed moderate/severe hypoxic-ischemic encephalopathy after birth will receive routine therapy and be randomized to four arms for allogenic neural progenitor cells transplantation，paracrine factors of human mesenchymal stem cells intrathecal injection，combination of cell and factor or only routine therapy. patients will be followed for neurodevelopmental outcome at 12 and 18 months in pediatrics of navy general hospital. magnetic resonance imaging, electroencephalogram, bailey scores, peabody development measure scale and gross motor function measure assessment will be obtained in the following research.results will be analyzed and described in study reports.

Eligibility criteria:
inclusion criteria: 1. gestational age ≥ 34weeks, body weight ≥ 2kg. 2. 1 minute apgar score ≤3, and 5 minutes apgar score ≤5, or umbilical arterial blood gas potential of hydrogen\<7.0, or 30 minutes base excess≤-12 mmol/l, or need for ventilation 5 minutes after birth. 3. all infants must have signs of encephalopathy (such as convulsion, coma, dystonia, abnormal primitive reflex and irregular respiration) within 6 hours of age or continued abnormal eeg for more than 24h. exclusion criteria: 1. does not meet the inclusion criteria 2. suffer from other serious organic disease or congenital, hereditary metabolic diseases 3. intracranial active infection, or neuromuscular damage outside central nervous system 4. potential of hydrogen / electrolyte disorders without improvement or stability 5. coagulation disorders associated with bleeding tendency 6. immune function is not perfect 7. patients or his guardian refuse consent. 8. patients or his guardian don't accept the follow-up schedule.

Keywords: hypoxic-ischemic encephalopathy progenitor cell paracrine factor adipose mesenchymal stem cell neonate
velopharyngeal insufficiency evaluation post cleft palate repair. furlow with buccinator myomucosal flap versus two flap palatoplasty

Conditions: Cleft Palate

Summary: cleft palate is one of the most common congenital abnormalities of the orofacial region throughout the world. this condition can cause facial deformity, feeding problems, frequent middle ear infections, dental defects, speech abnormalities and emotional problems . early surgical repair of this congenital anomaly prevents the psychological and functional problems associated with the deformity . patients may develop various complications after primary palatoplasty including palatal fistula and velopharyngeal insufficiency (vpi) which are relatively common . the main goal of cleft palate repair is to achieve normal speech and adequate velopharyngeal function with minimal effect on facial growth. the primary objective in the surgical repair of a cleft palate is the development of normal speech. speech quality remains the most important standard for assessing clinical outcomes and the success of surgical procedures. many surgical techniques for palate correction have been described determining the most effective technique for the surgical repair of palatal clefts continues to cause controversy . the incidence of vpi post cleft palate repair is 20-30% of patients . if there is significant velopharyngeal dysfunction during normal speech development, many children learn to compensate for the lack of intraoral pressure. they produce a hoarse voice because of vocal fold adduction and sudden release. compared with the adductor vocal fold palsy .


Eligibility criteria:
inclusion criteria: * •children more than 3 years old * type of cleft: isolated cleft palate exclusion criteri * complicated cases by fistula or redo, * missed follow up; less than 6 months.